- Home
- GLNG vs TVTX Comparison
GLNG vs TVTX Comparison
Compare GLNG & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLNG | TVTX |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLNG | TVTX |
|---|---|---|
| Price | $37.07 | $40.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $51.13 | $37.21 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 333.77 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | $326,627,000.00 | ★ $435,826,000.00 |
| Revenue This Year | $50.18 | $120.02 |
| Revenue Next Year | $0.91 | $37.00 |
| P/E Ratio | $67.01 | ★ N/A |
| Revenue Growth | 19.15 | ★ 114.22 |
| 52 Week Low | $29.56 | $12.91 |
| 52 Week High | $45.98 | $42.13 |
Technical Indicators
Market Signals| Indicator | GLNG | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 67.72 |
| Support Level | $36.75 | $33.49 |
| Resistance Level | $38.39 | $42.13 |
| Average True Range (ATR) | 0.80 | 1.92 |
| MACD | 0.03 | 0.39 |
| Stochastic Oscillator | 21.96 | 75.98 |
Price Performance
Historical ComparisonAbout GLNG Golar Lng Ltd
Golar LNG Ltd is a midstream LNG company that operates in the transportation, regasification, liquefaction, and trading of LNG. The segment in which the group operates includes Shipping, FLNG (Floating Liquefaction Natural Gas vessels), and Corporate and other. It generates maximum revenue from the FLNG segment.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.